Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote

LEXICON PHARMACEUTICALS, INC.

Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.
Licensed sotagliflozin to Viatris for ex-U.S./Europe markets; $25M upfront, up to $197M milestones.
ZYNQUISTA AdCom voted 11-3 that benefits do not outweigh risks; PDUFA target Dec 20, 2024.
INPEFA net sales $1.7M; field force reduced ~50% in September to focus on targeted prescribers.
LX9211 Phase 2b DPNP screening complete, topline data now expected Q1 2025; LX9851 IND on track mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.